Researchers have found that methylnaltrexone, a peripherally acting µ-opioid receptor antagonist, may offer an effective solution to relieving patients' opioid-induced constipation with minimal adverse effects.
The FDA approval of pembrolizumab plus lenvatinib for this new indication is the first under a new international collaboration with Australia and Canada.
Two phase 3 studies showed that ofatumumab was superior to teriflunomide (Aubagio) in patients with relapsing forms of multiple sclerosis.
Research demonstrates a new direction in cell signaling and treatment for chronic inflammatory diseases such as psoriasis, asthma, and HIV.
The annual National Association of Specialty Pharmacy annual meeting shed light on the significant role these caregivers play in patient care.
The significant jump in hospital-owned specialty pharmacies bolsters the belief that health system leaders increasingly understand how these services enable their organizations to enhance patient care and achieve market differentiation.
The parties included in this agreement in principle represent some of the more than 2,600 lawsuits filed against Purdue Pharma concerning opioids, including the company’s OxyContin products.
A new study identified pathways that may serve as therapeutic targets for overcoming drug resistance in acute myeloid leukemia.
An over-the-counter and prescription drug, ranitidine is an H2 (histamine-2) blocker that decreases the amount of acid created by the stomach.
Tenapanor, a novel treatment, is a minimally-absorbed small molecule that acts locally in the gastrointestinal (GI) tract to inhibit the sodium-hydrogen exchanger NHE3.
Top news of the week from Specialty Pharmacy Times.
Study finds association between obesity and a greater burden of symptoms and distress among patients with breast or prostate cancer.
As an increasing number of youth are using e-cigarette products, the FDA has announced a federal plan intended to clear the market of unauthorized, nontobacco-flavored e-cigarette products.
Puma’s supplemental New Drug Application is seeking approval for the use neratinib (Nerlynx) plus capecitabine as a third-line treatment in patients with human epidermal growth receptor 2-positive metastatic breast cancer.
London Mayor Sadiq Khan has called for broader availability of pre-exposure prophylaxis drugs in his welcoming speech at the Fast-Track Cities 2019 conference, where leaders from 300 cities around the world will discuss municipal responses to HIV, tuberculosis, and viral hepatitis.
+ Load More